This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Neurodegenerative Diseases Market To 2018 - New Product Entries In Both Niche And Broader Parkinson's Disease Treatment Will Boost Market Despite Patent Cliff

NEW YORK, March 27, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Neurodegenerative Diseases Market to 2018 - New product entries in both niche and broader Parkinson's disease treatment will boost market despite patent cliff

http://www.reportlinker.com/p01154050/Neurodegenerative-Diseases-Market-to-2018---New-product-entries-in-both-niche-and-broader-Parkinson's-disease-treatment-will-boost-market-despite-patent-cliff.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology

Neurodegenerative Diseases Market to 2018 - New product entries in both niche and broader Parkinson's disease treatment will boost market despite patent cliff

Summary

GBI Research, the leading business intelligence provider, has released its latest research "Neurodegenerative Diseases Market to 2018 - New product entries in both niche and broader Parkinson's disease treatment will boost market despite patent cliff". A highly dynamic market scenario is expected in Neurodegenerative diseases in the next few years, with a number of patent expiries and anticipated new drug approvals. The market for Alzheimer's disease has not seen any recent major breakthroughs, and is expected to experience a decline due to the patent expiry of several major products. The market for Parkinson's disease, on the other hand, is expected to experience growth due to the anticipated approval of expensive products such as Duodopa in the US, in spite of the fact that it will soon hit its own patent cliff. Additionally, the overall aging of populations the developed world is expected to increase the number of patients suffering from these diseases due to their relatively high prevalence in the elderly. Scope

- The report analyzes treatment usage patterns, market characterization, pipeline analysis, and key M&A and licensing deal trends in Alzheimer's Disease (AD), Parkinson's Disease (PD), Amyotrophic Lateral Sclerosis (ALS) and Huntington's Disease (HD).

- The current therapeutic environment in the treatment of AD, PD, HD and ALS across the top seven developed markets, including the US, Germany, France, the UK, Italy, Spain and Japan.

- Market data on the geographical landscape and therapeutic landscape, including market size, annual cost of therapy, treatment usage patterns such as disease population and prescription populations.

1 of 12

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

Chart of I:DJI
DOW 17,598.20 -91.66 -0.52%
S&P 500 2,098.04 -5.80 -0.28%
NASDAQ 5,115.3820 -12.8990 -0.25%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs